- Home
- DCI vs QGEN Comparison
DCI vs QGEN Comparison
Compare DCI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | QGEN |
|---|---|---|
| Founded | 1915 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.2B |
| IPO Year | 1987 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DCI | QGEN |
|---|---|---|
| Price | $90.33 | $45.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $92.50 | $50.07 |
| AVG Volume (30 Days) | 810.5K | ★ 1.2M |
| Earning Date | 12-04-2025 | 02-04-2026 |
| Dividend Yield | 1.32% | ★ 3.31% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | ★ 3.21 | 1.84 |
| Revenue | ★ $3,726,200,000.00 | $2,070,781,000.00 |
| Revenue This Year | $4.61 | $7.07 |
| Revenue Next Year | $4.58 | $6.14 |
| P/E Ratio | $28.37 | ★ $24.80 |
| Revenue Growth | 2.37 | ★ 5.32 |
| 52 Week Low | $57.45 | $37.63 |
| 52 Week High | $95.00 | $51.88 |
Technical Indicators
Market Signals| Indicator | DCI | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 46.10 |
| Support Level | $90.13 | $45.13 |
| Resistance Level | $93.52 | $46.02 |
| Average True Range (ATR) | 1.36 | 0.61 |
| MACD | -0.41 | -0.01 |
| Stochastic Oscillator | 2.01 | 52.41 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).